Home ContractsPHE - Corporate - Acute Drug Harms Surveillance an…

PHE - Corporate - Acute Drug Harms Surveillance and Early Warning System in UK

WAC ID:226773

NHS & HealthcareAward noticeClosedSME-friendly

Source:	Contracts Finder
Notice Type:	Award notice
Buyer:	Public Health England
Main Category:	Services
Procurement Method:	Open procedure (below threshold)
Tender Status:	Closed
Estimated Value (ex. VAT):	Not specified
Release Date:	14 April 2023
Application Deadline:	12 July 2021
Contract Start Date:	31 August 2021

View Original Notice

Access the full notice on the official portal

🤝 Need a consortium or subcontracting partner?

SMEs & Primes team up to win opportunities like this. Find partners on the board.

Find partners →

Award outcome

Awarded to

Newcastle UniversityGB-CFS-183680

Award value:	£99,676
Award decision date:	5 September 2021
Award status:	Active

Contracting Authority

Organisation

Public Health England

Submission Details

Description

Public Health England (PHE) is seeking to commission an external partner with an existing system and / or capability to deliver an opioid and new psychoactive substances (NPS) clinical harms surveillance programme. The programme will: • rapidly detect any incident involving synthetic opioids in the heroin or cocaine markets; • monitor the emergence of a synthetic opioid market as seen in North America; • identify health harms associated with toxicity from emerging/new NPS, such as synthetic cannabinoids. The programme will involve laboratory testing of biological samples from A&E patients around the UK who have been treated for adverse reactions to illicit drugs. Participating A&E departments will take and submit biological samples from suitable patients. These samples will be toxicologically analysed and assessed, alongside other intelligence sources. Any emerging trends and signals of interest will be reported to PHE to ensure that drug health harms are identified and acted upon promptly.